iSAEC, UC San Diego partner for research into DIRI genetics

23rd August 2012 (Last Updated August 23rd, 2012 18:30)

The International Serious Adverse Events Consortium (iSAEC), the University of California, San Diego School of Medicine and UC San Diego Skaggs School of Pharmacy and Pharmaceutical Science will collaborate on research into the genetics of drug-induced renal injury (DIRI).

The International Serious Adverse Events Consortium (iSAEC), the University of California, San Diego School of Medicine and UC San Diego Skaggs School of Pharmacy and Pharmaceutical Science will collaborate on research into the genetics of drug-induced renal injury (DIRI).

The International Drug Induced Renal Injury Consortium (DIRECT) will be supported by the NIH-funded O'Brien Center, a collaborative research endeavour between the University of Alabama at Birmingham and the University of California, San Diego, for Acute Kidney Injury Research.

iSAEC chairman Arthur L Holden said; "To better understand the full genetic effects contributing to these diseases, we need to develop a large and diverse collection of research subjects, in conjunction with international clinical researchers who share our strong interest and have experience with DIRI reactions."

The patients with serious drug-induced renal injury reactions will be recruited by DIRECT through a collaborative network, including clinical research centres around the world.

The partnership follows a research strategy that focuses on key causal drugs and diverse populations groups that experience the adverse drug reaction.

The UCSD O'Brien Center Nephrology professor of clinical medicine, associate chair for clinical research, department of medicine, principal investigator Dr Ravindra Mehta said the aim is to develop simple genetic tests so that drug therapy can be personalised and those at risk of kidney reactions can be prescribed to safely.

"The main aim of the project is to define the genetic risk factors predisposing to DIRI in order to develop strategies for individualisation of drug therapy to maximise benefits and minimise harm," Mehta said.